Roland Seiler

List of Publications by Year in Descending Order

83 papers	2,199 citations	23 h-index	45 g-index
94 ext. papers	2,991 ext. citations	5.2 avg, IF	4.66 L-index

#	Paper	IF	Citations
83	A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. *Scientific Reports*, **2021**, 11, 5849	4.9	1
82	Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study. *Journal of Urology*, **2021**, 205, 1629-1640	2.5	2
81	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. *Translational Andrology and Urology*, **2021**, 10, 4036-4050	2.3	1
80	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. *European Urology*, **2021**, 80, 149-159	10.2	5
79	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 498.e1-498.e11	2.8	0
78	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. *Cell Reports Medicine*, **2021**, 2, 100382	18	1
77	Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer. *Bladder Cancer*, **2020**, 6, 525-535	1	
76	Genomic Subtyping in Bladder Cancer. *Current Urology Reports*, **2020**, 21, 9	2.9	9
75	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. *European Urology Oncology*, **2020**, 3, 420-423	6.7	11
74	Eine Vision f□die Zeitschrift f□Sportpsychologie. *Zeitschrift Fur Sportpsychologie*, **2020**, 27, 13-19	0.3	
73	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 262-268	2.8	9
72	Re: Aur□e Kamoun, Aur□en de Reyni□, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network. *European Urology*, **2020**, 77, e105-e106	10.2	12
71	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial	2.5	3
70	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 851.e19-851.e25	2.8	2
69	Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	19
68	Re: A Clonal Expression Biomarker Associates with Lung Cancer Mortality. *European Urology*, **2020**, 78, 925-926	10.2	
67	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 2210-2220	6.1	5

66	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 858-866	2.8	8
65	New horizons in bladder cancer research. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 867-885	2.8	4
64	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. *European Urology*, **2020**, 77, 420-433	10.2	309
63	Team Cognition in Sport: How Current Insights Into How Teamwork Is Achieved in Naturalistic Settings Can Lead to Simulation Studies. *Frontiers in Psychology*, **2019**, 10, 2082	3.4	7
62	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 826-836	2.8	15
61	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. *European Urology*, **2019**, 76, 59-68	10.2	63
60	Molecular landscape of carcinoma invading bladder muscle: does patient age matter?. *BJU International*, **2019**, 124, 719-721	5.6	3
59	Molecular Characterization of Neuroendocrine-like Bladder Cancer. *Clinical Cancer Research*, **2019**, 25, 3908-3920	12.9	42
58	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 573.e19-573.e29	2.8	3
57	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. *Genome Medicine*, **2019**, 11, 60	14.4	21
56	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. *American Journal of Surgical Pathology*, **2019**, 43, 1600-1610	6.7	15
55	Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. *World Journal of Urology*, **2019**, 37, 85-93	4	14
54	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. *Clinical Cancer Research*, **2019**, 25, 5082-5093	12.9	50
53	Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?. *World Journal of Urology*, **2019**, 37, 1759-1765	4	7
52	Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 818-825	2.8	13
51	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. *European Urology Focus*, **2019**, 5, 681-688	5.1	26
50	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 238.e19-238.e27	2.8	2
49	Unravelling disparate roles of NOTCH in bladder cancer. *Nature Reviews Urology*, **2018**, 15, 345-357	5.5	29

48	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 342.e7-342.e14	2.8	5
47	Robot-assisted versus open cystectomy. *Lancet, The*, **2018**, 391, 2479-2480	40	2
46	Strukturmerkmale des Berufsfelds Sportpsychologie in der Schweiz. *Zeitschrift Fur Sportpsychologie* , **2018**, 25, 33-44	0.3	2
45	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 413-422	2.8	16
44	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 2746-2755	6.1	34
43	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. *Bladder Cancer*, **2018**, 4, 19-29	1	25
42	Achieving teamwork in naturalistic sport settings: An exploratory qualitative study of informational resources supporting football playersTactivity when coordinating with others. *Psychology of Sport and Exercise*, **2018**, 38, 154-166	4.2	8
41	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. *Scientific Reports*, **2017**, 7, 42713	4.9	58
40	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 458.e1-458.e7	2.8	6
39	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. *European Urology*, **2017**, 72, 544-554	10.2	411
38	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. *European Urology*, **2017**, 72, 142-150	10.2	29
37	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. *JAMA Oncology*, **2017**, 3, 1663-1672	13.4	138
36	Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	9
35	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. *Oncotarget*, **2017**, 8, 50804-50813	3.3	27
34	Different stages in drug development for muscle-invasive bladder cancer. *Translational Andrology and Urology*, **2017**, 6, 1060-1066	2.3	2
33	Evasion of immunosurveillance by genomic alterations of PPAR/RXR in bladder cancer. *Nature Communications*, **2017**, 8, 103	17.4	66
32	A low or high BMI is a risk factor for renal hematoma after extracorporeal shock wave lithotripsy for kidney stones. *Urolithiasis*, **2017**, 45, 317-321	3.2	7
31	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. *International Journal of Urology*, **2017**, 24, 7-15	2.3	10

30	Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 437-51	2.8	18
29	Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. *European Urology*, **2016**, 70, 1076	10.2	
28	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 469-76	2.8	7
27	Does Stepwise Voltage Ramping Protect the Kidney from Injury During Extracorporeal Shockwave Lithotripsy? Results of a Prospective Randomized Trial. *European Urology*, **2016**, 69, 267-73	10.2	34
26	Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. *Oncotarget*, **2016**, 7, 15747-56	3.3	12
25	Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. *Translational Andrology and Urology*, **2016**, 5, 271-3	2.3	3
24	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. *Journal of Urology*, **2016**, 196, 1036-41	2.5	24
23	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. *Journal of Urology*, **2015**, 194, 1120-31	2.5	45
22	Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 166.e1-8	2.8	12
21	Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial. *Journal of Urology*, **2015**, 194, 418-23	2.5	15
20	FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. *Journal of Urology*, **2015**, 193, 325-30	2.5	23
19	Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin.. *Journal of Clinical Oncology*, **2015**, 33, 4512-4512	2.2	4
18	Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. *Journal of Urology*, **2014**, 191, 1280-5	2.5	59
17	CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. *Modern Pathology*, **2014**, 27, 87-95	9.8	59
16	Assessing the quality of studies on the diagnostic accuracy of tumor markers. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1051-60	2.8	15
15	Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. *Prostate*, **2014**, 74, 1647-54	4.2	16
14	Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. *American Journal of Surgical Pathology*, **2014**, 38, 325-32	6.7	28
13	Pelvic lymph node dissection in the context of radical cystectomy: a thorough insight into the connection between patient, surgeon, pathologist and treating institution. *Research and Reports in Urology*, **2013**, 5, 121-8	1.3	2

12	High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients. *Human Pathology*, **2012**, 43, 269-75	3.7	8
11	Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. *Histopathology*, **2011**, 58, 571-8	7.3	19
10	Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. *European Urology*, **2011**, 60, 350-7	10.2	106
9	Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. *Prostate*, **2011**, 71, 453-60	4.2	28
8	MMP-2 and MMP-9 in lymph-node-positive bladder cancer. *Journal of Clinical Pathology*, **2011**, 64, 1078-82	3.9	15
7	Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. *Journal of Clinical Pathology*, **2010**, 63, 504-7	3.9	18
6	Angewandte Sportpsychologie in der Schweiz: Ausbildungskonzeption und Berufsfeldperspektiven. *Zeitschrift Fur Sportpsychologie*, **2009**, 16, 29-34	0.3	5
5	Role of beta1-, beta2-, and beta3-adrenoceptors in contractile hypersensitivity in a model of small bowel transplantation. *Surgery*, **2008**, 143, 94-102	3.6	9
4	Role of selective alpha and beta adrenergic receptor mechanisms in rat jejunal longitudinal muscle contractility. *Journal of Gastrointestinal Surgery*, **2008**, 12, 1087-93	3.3	13
3	alpha- and beta-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle. *Journal of Gastrointestinal Surgery*, **2005**, 9, 227-35	3.3	14
2	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. *SSRN Electronic Journal*,	1	8
1	The consensus molecular classification of muscle-invasive bladder cancer		6